What Barkat Pharmaceutical Group does

Barkat Pharmaceutical Group (گروه دارویی برکت) is an Iranian pharmaceutical holding company headquartered in Tehran, operating as a publicly listed entity on the Tehran Stock Exchange under the ticker برکت. Founded in 2010 as Tadbir Novin Pharmaceutical Technology Company and affiliated with the Executive Headquarters of Imam's Order (ستاد اجرایی فرمان امام), the group controls more than 20 wholly-owned subsidiaries covering the full pharmaceutical value chain — from R&D and active pharmaceutical ingredient manufacturing through nationwide distribution via subsidiary Alborz Distribution. Its manufacturing footprint includes the Barkat Pharmaceutical Industrial Town in Tehran, Alborz Darou in Qazvin, and Sobhan Oncology in Rasht, with more than 3,500 healthcare specialists employed across the group.

The group's technology platform spans biotechnology, drug delivery systems (nanotechnology and sustained-release formulations), and cellular-molecular technologies including cell therapy, gene therapy, immunotherapy, and tissue engineering. Core products include the inactivated COVID-19 vaccine Coviran Barakat (BIV1-CovIran) and its Omicron-specific variant Barakat Plus, anti-cancer vaccines and drugs, cardiovascular and multiple sclerosis vaccine production lines, cell-therapy products for vitiligo (CellTech Pharmed), Remdesivir, and general pharmaceutical generics manufactured under GMP conditions. Revenue is generated through product sales across three streams — pharmaceutical product sales, vaccine production, and advanced biological products — distributed domestically through government healthcare networks, hospitals, and pharmacy networks, and exported to government buyers in Venezuela and Nicaragua. Pricing is governed by Iran's national pharmaceutical pricing regulations and is not publicly disclosed.

Name

Barkat Pharmaceutical Group

Legal name

Barkat Pharmaceutical Group (شرکت گروه دارویی برکت)

Website

https://bpharmed.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Barkat Pharmaceutical Group is an Iranian publicly listed pharmaceutical holding company operating 20+ subsidiaries that develop, manufacture, and distribute vaccines, biologics, cell therapies, oncology drugs, and generics across Iran, with exports to Venezuela and Nicaragua.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical manufacturing
• Biotechnology products
• Vaccine production
• Cell therapy drugs
• Oncology medications

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of manufactured pharmaceutical products including generic drugs, biologics, and specialty medications through a network of subsidiary companies. Products are distributed domestically through pharmacies, hospitals, and government healthcare networks, and exported to regional markets.
2. Vaccine Production and Sales: Production and sale of COVID-19 vaccines (Coviran Barakat, Barakat Plus) and other vaccines. Vaccines have been exported to Venezuela and Nicaragua.
3. Biological Products: Production and sale of advanced biological products including cell-based therapies for vitiligo treatment (CellTech Pharmed) and oncology products (Sobhan Oncology).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Barkat Pharmaceutical Group is a publicly listed Iranian pharmaceutical holding company that develops, manufactures, and distributes generic drugs, biologics, vaccines, and specialty therapies through more than 20 subsidiaries. Its core offerings include COVID-19 vaccines (Coviran Barakat, Barakat Plus), cell therapy products for vitiligo, oncology drugs, and advanced biologics, distributed across Iran's healthcare network and exported to regional markets.

Product overview

Barkat Pharmaceutical Group operates as a diversified pharmaceutical holding company with more than 20 subsidiaries, offering a broad portfolio of pharmaceutical and biotechnology products. The product portfolio includes COVID-19 vaccines (Coviran Barakat and Barakat Plus), cancer treatment products (anti-cancer vaccines and drugs from subsidiaries like Sobhan Oncology), cell therapy products (Cell Tech Pharmed for vitiligo treatment), and general pharmaceutical medications. The group also produces Remdesivir and other antiviral medications, with products manufactured under GMP conditions and approved by Iran's Food and Drug Organization.

Differentiator

Problem solved

Functional benefit

Brands

• Coviran Barakat: COVID-19 vaccine developed by Barkat Pharmaceutical Group and Shafa Pharmed subsidiary.
• Barakat Plus

Products and services

• Coviran Barakat (BIV1-CovIran) COVID-19 Vaccine Inactivated COVID-19 vaccine developed by Barkat Pharmaceutical Group's Shafa Pharmed subsidiary; manufactured under GMP conditions and approved by Iran's Food and Drug Organization, with documented 87.1% effectiveness against positive test, 86.4% against hospitalization, and 98.3% against death.
• Barakat Plus (Omicron-specific COVID-19 Vaccine) Omicron-specific COVID-19 vaccine developed by Barkat Pharmaceutical Group that received public consumption authorization from Iran's Ministry of Health in July 2022 for general public use.
• CellTech Pharmed Vitiligo Biological Treatment Products Biological products for treating vitiligo (leukoderma) including cell therapy products and Platc as raw material for cellular production, manufactured under GMP conditions and approved by Iran's FDA.
• Remdesivir Antiviral Medication Antiviral medication produced by Sobhan Oncology subsidiary of Barkat Pharmaceutical Group during the COVID-19 pandemic period.
• Anti-Cancer Vaccines and Cardiovascular / MS Drugs Specialty medications including anti-cancer vaccines, cardiovascular disease treatments, and multiple sclerosis drugs produced at Barkat Pharmaceutical Industrial Town through the group's biotechnology capabilities.
• Five Anti-Cancer and Anti-Fungal Drugs A set of five new anti-cancer and anti-fungal pharmaceutical drugs unveiled by Barkat Pharmaceutical Group through its subsidiary operations.

Quantifiable outcome

• COVID-19 vaccine effectiveness: 87.1% against positive test, 86.4% against hospitalization, 98.3% against death (higher than AstraZeneca, Sinopharm, and Sputnik V in comparative studies)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Taamin Pharmaceutical Investment (سرمایه گذاری دارویی تأمین)coreStrategic or Co-development Partner · 8 October 2022A memorandum of understanding was signed between Barkat Pharmaceutical Group and Taamin Pharmaceutical Investment during the 7th Iran Pharma exhibition. The partnership aims to support Iranian pharmaceutical exports and develop and expand exports of pharmaceutical and health-oriented products. Goals include synergistic introduction of products from subsidiaries, shared infrastructure utilization for export expansion, joint market studies and evaluation, cost reduction through government and private networks, and cooperation in facilitating and removing export barriers through follow-up with upstream authorities.
• Shafapharm (شفا فارمد)coreTechnology or IntegrationShafapharm is a subsidiary of Barkat Pharmaceutical Group and produced Coviran Barakat COVID-19 vaccine. It is one of the key biotechnology manufacturing subsidiaries within the group.
• Sobhan Oncology (سبحان انکولوژی)coreTechnology or IntegrationSobhan Oncology is a subsidiary of Barkat Pharmaceutical Group specializing in oncology medications. It achieved approximately 45% market share in Iran's oncology market and played a critical role in producing Remdesivir during the COVID-19 pandemic.
• CellTech Pharmed (سل تک فارمد)coreTechnology or IntegrationCellTech Pharmed is a subsidiary specializing in cell therapy and biotechnology products. It produces biological products for vitiligo treatment and Platect as raw material for cell therapy, including living human cells for therapeutic applications. Launched two knowledge-based products in the 7th National Health Tech Mart.
• Executive Headquarters of Imam's Order (ستاد اجرایی فرمان امام)coreOthersBarkat Pharmaceutical Group is affiliated with the Executive Headquarters of Imam's Order (ستاد اجرایی فرمان امام), which is the parent organization overseeing the group's operations and strategic direction. Key figures including Seyed Parviz Fattah, Head of the Executive Headquarters of Imam's Order, have visited Barkat facilities and attended annual general meetings.
• Medical Universities and Clinical Research PartnersminorStrategic or Co-development PartnerBarkat Pharmaceutical Group collaborates with universities and clinical research centers for the development and clinical testing of pharmaceutical products, including the Phase 1 and 2 clinical trials of Coviran Barakat vaccine conducted with academic medical centers.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Emerging players

• BioNTech: Biotech company focused on mRNA vaccines and immuno-oncology. Comparable as a peer on the cell/gene/vaccine technology axis, particularly relevant for Barkat's investments in mRNA-adjacent platforms, immunotherapy, and oncology pipelines.

Direct peers

• Darou Pakhsh Pharmaceutical Manufacturing Company: One of Iran's largest pharmaceutical manufacturers and a direct domestic competitor. Comparable as a broad-based Iranian pharma producer with branded generics, distribution, and government-tied procurement, mirroring Barkat's integrated model in the same end market.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest pharma manufacturers in the MENA region, producing generics across multiple dosage forms. Comparable given similar scale, broad product portfolio, and government-influenced healthcare procurement in Egypt.
• Tehran Pharma (TPICO): Major Iranian pharmaceutical manufacturer producing tablets, capsules, syrups, and injectables. Directly comparable given overlapping product formats, distribution through Iranian healthcare networks, and a similarly broad generics-plus-specialty portfolio.

Broad incumbents

• SPIMACO Addwaeih: Saudi Arabia's flagship pharmaceutical manufacturer with branded generics, sterile injectables, and biologics capabilities. Comparable as a state-linked regional pharma champion pursuing self-sufficiency in essential medicines.
• Hikma Pharmaceuticals: MENA-headquartered multinational specialty pharmaceutical company with strong generics, injectables, and branded business. Comparable as a regionally anchored pharma player with similar therapeutic area mix and emerging-markets distribution muscle.
• Sinopharm (China National Pharmaceutical Group): Chinese state-linked pharmaceutical conglomerate with vaccine (BBIBP-CorV), biologics, and large-scale manufacturing operations. Comparable as a state-affiliated vaccine and biologics producer with government backing and export ambitions.
• Cipla: Indian global pharmaceutical company with strong generics and respiratory/specialty footprint in emerging markets. Comparable given a similarly broad portfolio, focus on affordable medicines, and emerging-market commercial model.
• Julphar (Gulf Pharmaceutical Industries): Largest pharmaceutical manufacturer in the Middle East, producing generics, branded drugs, and biotech products across MENA. Comparable as a regionally anchored generics-and-biologics manufacturer operating in similar regulatory and pricing regimes.
• Aurobindo Pharma: Large Indian generics manufacturer with growing biologics/vaccine capabilities through subsidiaries like AuroVaccines. Comparable as a vertically integrated manufacturer scaling into biosimilars and vaccines for emerging markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/barkat-pharmed-co

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barkat Pharmaceutical Group